Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 390

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 390
---
, 2023 (Predecessor)    |     |             |     25 |   |     | $         | 8,378.40 |     |             | 6.86 |
| Options cancelled (Predecessor)             |     |             |    (25 | ) |     | $         | 8,378.40 |     |             |      |
| Balance, February 14, 2024 (Predecessor)    |     |             |      - |   |     | $         |        - |     |             |    - |
| Balance, February 14, 2024 (Predecessor)    |     |             |      - |   |     | $         |        - |     |             |    - |
| Options granted (Successor)                 |     |             |  4,909 |   |     | $         | 1,818.20 |     |             |    - |
| Options cancelled (Successor)               |     |             | (1,662 | ) |     | $         | 2,922.40 |     |             |    - |
| Balance, December 31, 2024 (Successor)      |     |             |  3,247 |   |     | $         |   200.00 |     |             | 9.64 |
| Options exercisable as of December 31, 2024 |     |             |  2,474 |   |     | $         |   200.00 |     |             | 9.68 |

The intrinsic value of Predecessor
options exercised during the year ended December 31, 2023 was $. No options were exercised in the Successor period from February
14, 2024 to December 31, 2024.

On March 25, 2024, the stockholders
approved the CERo Therapeutics Holdings, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) and 2024 Employee Stock Purchase
Plan (“2024 ESPP”), with an initial reserve of and shares of common stock, respectively. The 2024 Plan and 2024
ESPP became effective on February 14, 2024 in connection with the closing of the Business Combination. At a special meeting of stockholders
on April 30, 2024, the stockholders approved an increase in the number of shares available